Invivyd (IVVD) Cash & Equivalents (2020 - 2026)
Invivyd (IVVD) recorded Cash & Equivalents of $160.08 million in Q2 2026, up 358.6% from $34.91 million a year earlier.
Powered by 
Analysis
Invivyd (IVVD) Cash & Equivalents (2020 - 2026) Analysis & Trends
At the end of FY2025, Invivyd reported Cash & Equivalents of $226.69 million, up 226.9% from FY2024.
- Annual Cash & Equivalents has a five-year compound annual growth rate of 14.5% (FY2020 to FY2025).
- Across earlier years, Cash & Equivalents came in at $69.35 million in FY2024 (-65.4%), $200.64 million in FY2023 (+117.9%), $92.08 million in FY2022 (-83.0%) and $542.22 million in FY2021 (+371.5%).
- Quarterly Cash & Equivalents has ranged from $34.91 million in Q2 2025 to $542.22 million in Q4 2021 over the past five years.
- On a year-over-year basis, Cash & Equivalents rose in two of the last seven quarters, with growth averaging 43.9%.
- Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 371.5% in Q4 2021, against a decline of 83.0% in Q4 2022 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Invivyd | 241.70 Mn | -264.94 Mn | 13.01 Mn | 160.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 160.08 Mn |
| Dec 31, 2025 | 226.69 Mn |
| Sep 30, 2025 | 84.97 Mn |
| Jun 30, 2025 | 34.91 Mn |
| Mar 31, 2025 | 48.08 Mn |
| Dec 31, 2024 | 69.35 Mn |
| Sep 30, 2024 | 106.87 Mn |
| Jun 30, 2024 | 147.88 Mn |
| Mar 31, 2024 | 189.39 Mn |
| Dec 31, 2023 | 200.64 Mn |
| Sep 30, 2023 | 181.82 Mn |
| Jun 30, 2023 | 121.95 Mn |
| Mar 31, 2023 | 126.47 Mn |
| Dec 31, 2022 | 92.08 Mn |
| Sep 30, 2022 | 278.15 Mn |
| Jun 30, 2022 | 474.89 Mn |
| Mar 31, 2022 | 532.22 Mn |
| Dec 31, 2021 | 542.22 Mn |
| Sep 30, 2021 | 478.27 Mn |
| Jun 30, 2021 | 392.51 Mn |
API Access
Invivyd Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=IVVD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "IVVD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=IVVD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();